Would you consider age of 70 years as a contraindication (without any other cardiac risks) to use anthracycline in a triple negative breast cancer patient?

As always, it depends. The DFS advantage for anthracycline-based regimens over TCx6 in the ABC trials (J Clin Oncol 35:2647, 2017) was for patients with lymph node involvement, so they were at high risk. In a fit woman who is age 70 or older, the benefits of including the anthracycline likely outwei...